David Hutton

According to the company, no safety concerns with corneal endothelial health reported across all 3 trials, and the device delivered consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe.

The CLEAR Act would clarify the FDA’s authority to regulate products, including eye drops, after a court decision created unnecessary confusion and turmoil.

Genetic and clinical research reveals new type of macular dystrophy, a cause of central vision loss.

John Cooksey, who had an ophthalmology practice in Monroe, Louisiana, served three terms in the US House of Representatives. He also founded an eye clinic in Kenya.

As special pandemic rules end, a new analysis shows the potential impact on patients in some states and rural areas of others.

A team of investigators is researching the use of a new cell delivery method to help cells stick and stay where they are needed most.

After 10 years, AREDS2 formula shows increased efficacy compared to original formula, benefit of eliminating beta-carotene.

Scientists have revived light-sensing neuron cells in organ donor eyes and restored communication between them as part of a series of discoveries that stand to transform brain and vision research.

With clearer imaging and enhanced resolution, the new OCT approach could improve medical diagnostic imaging.

According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.

Vision Buddy is offering a headset that features modes for TV/movie streaming, magnification, and reading, helping the visually impaired improve their quality of life.

The companies are marketing the first FDA-approved ophthalmology biosimilar as a treatment option for patients with retinal disorders.

According to the company, the AI platform can predict a person's risk of having a stroke or a heart attack in the next five years.

According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular edema patients.

Faricimab is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

The company noted that pegcetacoplan, designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases, was granted Fast Track designation by the FDA for the treatment of geographic atrophy.

The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration.

The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

Outlook Therapeutics initially filed the BLA fin March or the use of bevacizumab-vikg in the treatment of wet AMD. The company said it wlll re-submit a revised BLA by September.

According to researchers from the Doherty Institute, the cornea produces a delicate and limited immune response to fight infections without damaging a patient's vision.

Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

A new technique will allow fast and non-invasive assessment of the physiological state of the retina. This could be a real breakthrough in the treatment of eye diseases.

Retina Technologies Inc. is working on a modular digital vision screening platform it says will provide vision testing for the early detection of eye disorders.

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

The challenge is for ophthalmology students to have seen a range of pupil abnormalities before they are in a cubicle with a real patient. One solution to this challenge may be virtual reality.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease

According to the company, the ReCLAIM-2 study of elamipretide demonstrates a correlation between ellipsoid zone dysfunction and vision.

According to the company, a clinical trial evaluating Nyxol eye drops for night vision disturbances met FDA-agreed primary endpoint with subjects gaining 3 lines of low-contrast distance vision under dim light conditions compared to placebo.